Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM45Z3P)

• Drug Name: CD123/CLL1 CAR-T Cells Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 2/3	[1]

• Cross-matching ID: TTD Drug ID: DM45Z3P

Molecule-Related Drug Atlas

Drug(s) Targeting Myeloid inhibitory C-type lectin-like receptor (CD371)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CLL1 CAR-T Cell	DMUOMBZ	Acute myeloid leukaemia	2A60	Phase 2/3	[1]
CLL1-specific gene-engineered T cells	DMCT917	Acute myeloid leukaemia	2A60	Phase 1/2	[2]
CAR-T cells targeting CLL1	DMCPM92	leukaemia	2A60-2B33	Phase 1/2	[3]
Tepoditamab	DMC84Y9	Acute myelogenous leukaemia	2A41	Phase 1	[4]
CLL1-CD33 cCART cell therapy	DM5EM04	Acute myeloid leukaemia	2A60	Phase 1	[5]
CLT030	DM674MP	Acute myeloid leukaemia	2A60	Phase 1	[6]
KITE-222	DMPF49Z	Acute myeloid leukaemia	2A60	Phase 1	[7]
UCART-CLL1	DMT06MI	Multiple myeloma	2A83	Preclinical	[8]

Drug(s) Targeting Interleukin 3 receptor alpha (IL3RA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tagraxofusp	DM9HQ5U	Acute myeloid leukaemia	2A60	Approved	[9]
Talacotuzumab	DMARVFG	Acute myeloid leukaemia	2A60	Phase 2	[10]
MB-102	DMLPNVS	Acute kidney injury	GB60	Phase 2	[10]
Flotetuzumab	DMVR6OM	Acute biphenotypic leukaemia	2B33.4	Phase 2	[10]
4SCAR19 and 4SCAR123	DMYPQT4	B-cell lymphoma	2A86	Phase 1/2	[11]
SAR440234	DM6M8O4	Acute myeloid leukaemia	2A60	Phase 1/2	[12]
CD123-specific gene-engineered T cells	DMHOWU5	Acute myeloid leukaemia	2A60	Phase 1/2	[2]
CART-123 cells	DM0MCTJ	Acute myeloid leukaemia	2A60	Phase 1/2	[13]
CART-123 cells	DM0MCTJ	Acute myeloid leukaemia	2A60	Phase 1/2	[14]
Anti-CD123-CAR-transduced T cells	DMFV6TY	leukaemia	2A60-2B33	Phase 1/2	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 3 receptor alpha (IL3RA)	TTENHJ0	IL3RA_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]
Myeloid inhibitory C-type lectin-like receptor (CD371)	TT70N8V	CL12A_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]

References

• [1] ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML
• [2] ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
• [3] ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
• [4] MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opin Biol Ther. 2019 Jul;19(7):721-733.
• [5] Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
• [6] Clinical pipeline report, company report or official report of Cellerant Therapeutics.
• [7] Clinical pipeline report, company report or official report of Gilead
• [8] Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020 Mar;19(3):185-199.
• [9] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
• [12] Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
• [13] ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
• [14] ClinicalTrials.gov (NCT03556982) CART-123 FOR Relapsed/Refractory Acute Myelocytic LeukemiaAML
• [15] ClinicalTrials.gov (NCT02937103) A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies